The Native Antigen Company, contract service provider to the in vitro diagnostics industry based in Oxford, UK, has launched a new purified Bordetella pertussis toxin.

The toxin was developed in response to the increasing pressure on the in vitro diagnostics industry to supply highly specific, cost-effective antibody capture systems, which are needed to monitor vaccination programmes.

It is available in lyophilised format for ease of storage and use.

Pertussis, the condition caused by this bacterium, is a major cause of childhood morbidity and mortality.